Literature DB >> 27896521

PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment.

Angel Guerrero-Zotano1, Ingrid A Mayer1, Carlos L Arteaga2.   

Abstract

Anti-cancer cancer-targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Mutations in the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway are freqcuently found in breast cancers and associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK/mTOR are currently in clinical trials, mainly in combination with endocrine therapy and anti-HER2 therapy. These drugs are the focus of this review.

Entities:  

Keywords:  AKT; Breast cancer; PI3K; mTOR

Mesh：

Substances：

Year:  2016        PMID： 27896521     DOI： 10.1007/s10555-016-9637-x

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN： 0167-7659            Impact factor:   9.264


  122 in total

1.  Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer.

Authors:  Shuying Liu; Shunqiang Li; Bailiang Wang; Wenbin Liu; Mihai Gagea; Huiqin Chen; Joohyuk Sohn; Napa Parinyanitikul; Tina Primeau; Kim-Anh Do; George F Vande Woude; John Mendelsohn; Naoto T Ueno; Gordon B Mills; Debu Tripathy; Ana M Gonzalez-Angulo
Journal:  Mol Cancer Ther       Date:  2018-12-05       Impact factor: 6.261

2.  Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition.

Authors:  Yoko Katsuno; Dominique Stephan Meyer; Ziyang Zhang; Kevan M Shokat; Rosemary J Akhurst; Kohei Miyazono; Rik Derynck
Journal:  Sci Signal       Date:  2019-02-26       Impact factor: 8.192

Review 3.  Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.

Authors:  Tessa G Steenbruggen; Mette S van Ramshorst; Marleen Kok; Sabine C Linn; Carolien H Smorenburg; Gabe S Sonke
Journal:  Drugs       Date:  2017-08       Impact factor: 9.546

4.  Functional evaluation of synthetic flavonoids and chalcones for potential antiviral and anticancer properties.

Authors:  Nelly Mateeva; Suresh V K Eyunni; Kinfe K Redda; Ucheze Ononuju; Tony D Hansberry; Cecilia Aikens; Anita Nag
Journal:  Bioorg Med Chem Lett       Date:  2017-04-13       Impact factor: 2.823

5.  Treating breast cancer metastasis with cabazitaxel-loaded polymeric micelles.

Authors:  Tao Zhong; Bin He; Hai-Qiang Cao; Tao Tan; Hai-Yan Hu; Ya-Ping Li; Zhi-Wen Zhang
Journal:  Acta Pharmacol Sin       Date:  2017-05-01       Impact factor: 6.150

6.  Imbalance of the reciprocally inhibitory loop between the ubiquitin-specific protease USP43 and EGFR/PI3K/AKT drives breast carcinogenesis.

Authors:  Lin He; Xinhua Liu; Jianguo Yang; Wanjin Li; Shumeng Liu; Xujun Liu; Ziran Yang; Jie Ren; Yue Wang; Lin Shan; Chengjian Guan; Fei Pei; Liandi Lei; Yu Zhang; Xia Yi; Xiaohan Yang; Jing Liang; Rong Liu; Luyang Sun; Yongfeng Shang
Journal:  Cell Res       Date:  2018-08-22       Impact factor: 25.617

Review 7.  Comprehensive Review of Molecular Mechanisms and Clinical Features of Invasive Lobular Cancer.

Authors:  Nikhil Pramod; Akanksha Nigam; Mustafa Basree; Resham Mawalkar; Saba Mehra; Neelam Shinde; Gary Tozbikian; Nicole Williams; Sarmila Majumder; Bhuvaneswari Ramaswamy
Journal:  Oncologist       Date:  2021-03-16

8.  STEAP2 is down-regulated in breast cancer tissue and suppresses PI3K/AKT signaling and breast cancer cell invasion in vitro and in vivo.

Authors:  Qing Yang; Guoxin Ji; Jiyu Li
Journal:  Cancer Biol Ther       Date:  2019-11-07       Impact factor: 4.742

9.  Smad4 induces cell death in HO-8910 and SKOV3 ovarian carcinoma cell lines via PI3K-mTOR involvement.

Authors:  Yushuang Yao; Zhe Zhang; Fanmao Kong; Zhuqing Mao; Zhaoyuan Niu; Chuan Li; Aiping Chen
Journal:  Exp Biol Med (Maywood)       Date:  2020-04-10

10.  Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors.

Authors:  Emilie Clement; Hiroyuki Inuzuka; Naoe T Nihira; Wenyi Wei; Alex Toker
Journal:  Sci Signal       Date:  2018-03-13       Impact factor: 8.192
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.